Quick Comparison
| PEA (Palmitoylethanolamide) | PQQ | |
|---|---|---|
| Half-Life | 1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability | 3-5 hours (plasma), but effects on mitochondrial biogenesis persist |
| Typical Dosage | Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks. | Standard: 10-20 mg daily. Often combined with CoQ10 (100-300 mg) for synergistic mitochondrial support. Higher doses (40 mg) are used in some research settings. |
| Administration | Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability. | Oral (capsules, softgels). Best absorbed on an empty stomach. BioPQQ is the most studied branded form. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
PEA (Palmitoylethanolamide)
PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.
PQQ
PQQ activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional regulator of mitochondrial biogenesis. PGC-1alpha coactivates NRF-1 and NRF-2, which drive expression of mitochondrial transcription factor A (TFAM) and nuclear-encoded mitochondrial genes—the process of creating new mitochondria in existing cells. This is unique among commercially available supplements. PQQ also provides antioxidant protection through extremely efficient redox cycling at the N5 position; it can undergo thousands of oxidation-reduction cycles before being exhausted, estimated at 5,000x the efficiency of vitamin C. PQQ activates the CREB (cAMP response element-binding protein) signaling pathway and may enhance NGF signaling, supporting BDNF expression, synaptic plasticity, and neuronal survival.
Risks & Safety
PEA (Palmitoylethanolamide)
Common
Very well-tolerated — rare side effects. Mild GI discomfort.
Serious
None documented. Over 30 clinical trials confirm excellent safety profile.
Rare
Skin rash.
PQQ
Common
Very few — PQQ has an excellent safety profile at standard doses. Mild headache, fatigue initially.
Serious
No serious adverse effects documented.
Rare
Insomnia, irritability.
Full Profiles
PEA (Palmitoylethanolamide) →
An endogenous fatty acid amide produced naturally in the body in response to pain and inflammation. PEA activates PPAR-alpha receptors and indirectly enhances endocannabinoid signaling without binding to cannabinoid receptors. It has strong evidence for neuropathic pain, neuroinflammation, and neuroprotection. Unlike anti-inflammatory drugs, it resolves inflammation rather than merely suppressing it.
PQQ →
Pyrroloquinoline quinone is a redox cofactor that is the only known compound that can stimulate the growth of new mitochondria (mitochondrial biogenesis) in existing cells. Since mitochondrial density and function decline with age, PQQ addresses a root cause of age-related cognitive decline. It also provides potent antioxidant protection — estimated to be 5,000x more efficient at redox cycling than vitamin C.